Suppr超能文献

北美队列中家族性高胆固醇血症的分子特征

Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

作者信息

Garg Abhimanyu, Fazio Sergio, Duell P Barton, Baass Alexis, Udata Chandrasekhar, Joh Tenshang, Riel Tom, Sirota Marina, Dettling Danielle, Liang Hong, Garzone Pamela D, Gumbiner Barry, Wan Hong

机构信息

Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.

Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.

出版信息

J Endocr Soc. 2019 Nov 29;4(1):bvz015. doi: 10.1210/jendso/bvz015. eCollection 2020 Jan 1.

Abstract

BACKGROUND

Familial hypercholesterolemia (FH) confers a very high risk of premature cardiovascular disease and is commonly caused by mutations in low-density lipoprotein receptor ( apolipoprotein B (), or proprotein convertase subtilisin/kexin type 9 () and very rarely in LDLR adaptor protein 1 () genes.

OBJECTIVE

To determine the prevalence of pathogenic mutations in the , , and in a cohort of subjects who met Simon Broome criteria for FH and compare the clinical characteristics of mutation-positive and mutation-negative subjects.

METHODS

Ninety-three men and 107 women aged 19 to 80 years from lipid clinics in the United States and Canada participated. Demographic and historical data were collected, physical examination performed, and serum lipids/lipoproteins analyzed. Targeted sequencing analyses of and coding regions and exon 26 of were performed followed by detection of deletions and duplications.

RESULTS

Disease-causing and variants were identified in 114 and 6 subjects, respectively. Of the 58 variants, 8 were novel mutations. Compared with mutation-positive subjects, mutation-negative subjects were older (mean 49 years vs 57 years, respectively) and had a higher proportion of African Americans (1% vs 12.5%), higher prevalence of hypertension (21% vs 46%), and higher serum triglycerides (median 86 mg/dL vs 122 mg/dL) levels.

CONCLUSIONS

mutations were the most common cause of heterozygous FH in this North American cohort. A strikingly high proportion of FH subjects (40%) lacked mutations in known culprit genes. Identification of underlying genetic and environmental factors in mutation-negative patients is important to further our understanding of the metabolic basis of FH and other forms of severe hypercholesterolemia.

摘要

背景

家族性高胆固醇血症(FH)会带来极高的早发性心血管疾病风险,通常由低密度脂蛋白受体(LDLR)、载脂蛋白B(APOB)或枯草溶菌素/kexin 9型前蛋白转化酶(PCSK9)的突变引起,而LDLR衔接蛋白1(LDLRAP1)基因的突变则极为罕见。

目的

确定符合西蒙·布鲁姆FH标准的一组受试者中LDLR、APOB和PCSK9致病突变的患病率,并比较突变阳性和突变阴性受试者的临床特征。

方法

来自美国和加拿大脂质诊所的93名男性和107名年龄在19至80岁的女性参与了研究。收集了人口统计学和病史数据,进行了体格检查,并分析了血清脂质/脂蛋白。对LDLR和APOB的编码区以及PCSK9的第26外显子进行了靶向测序分析,随后检测了LDLRAP1的缺失和重复情况。

结果

分别在114名和6名受试者中鉴定出致病的LDLR和PCSK9变异。在58个APOB变异中,有8个是新突变。与突变阳性受试者相比,突变阴性受试者年龄更大(平均分别为49岁和57岁),非裔美国人比例更高(1%对12.5%),高血压患病率更高(21%对46%),血清甘油三酯水平更高(中位数86mg/dL对122mg/dL)。

结论

LDLR突变是该北美队列中杂合子FH最常见的原因。FH受试者中相当高比例(40%)在已知的致病基因中未发现突变。确定突变阴性患者潜在的遗传和环境因素对于加深我们对FH和其他严重高胆固醇血症形式的代谢基础的理解非常重要。

相似文献

1
Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.
J Endocr Soc. 2019 Nov 29;4(1):bvz015. doi: 10.1210/jendso/bvz015. eCollection 2020 Jan 1.
2
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Atherosclerosis. 2016 Oct;253:88-93. doi: 10.1016/j.atherosclerosis.2016.08.037. Epub 2016 Aug 26.
3
Molecular genetics of familial hypercholesterolemia in Israel-revisited.
Atherosclerosis. 2017 Feb;257:55-63. doi: 10.1016/j.atherosclerosis.2016.12.021. Epub 2016 Dec 18.
4
Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
J Clin Lipidol. 2016 May-Jun;10(3):547-555.e5. doi: 10.1016/j.jacl.2015.12.024. Epub 2016 Jan 6.
6
Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction.
Clin Cardiol. 2019 Mar;42(3):385-390. doi: 10.1002/clc.23154. Epub 2019 Feb 19.
8
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
Atheroscler Suppl. 2017 Oct;29:17-24. doi: 10.1016/j.atherosclerosissup.2017.07.002.
9
Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.
JACC Asia. 2021 Apr 21;1(1):82-89. doi: 10.1016/j.jacasi.2021.04.001. eCollection 2021 Jun.

引用本文的文献

1
New cardiovascular disease markers in patients with familial hypercholesterolemia carriers of genetic variants.
J Diabetes Metab Disord. 2024 Dec 16;24(1):13. doi: 10.1007/s40200-024-01537-w. eCollection 2025 Jun.
3
Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives.
Curr Atheroscler Rep. 2024 Oct;26(10):549-571. doi: 10.1007/s11883-024-01228-0. Epub 2024 Jul 15.
4
Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor.
Sci Transl Med. 2022 Sep 14;14(662):eabj8670. doi: 10.1126/scitranslmed.abj8670.
5
Health equity in the implementation of genomics and precision medicine: A public health imperative.
Genet Med. 2022 Aug;24(8):1630-1639. doi: 10.1016/j.gim.2022.04.009. Epub 2022 Apr 28.
6
Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model.
J Clin Endocrinol Metab. 2022 Mar 24;107(4):1078-1090. doi: 10.1210/clinem/dgab873.
7
Gene Participates in the Development of Primary Dyslipidemias.
Balkan J Med Genet. 2021 Jul 27;24(1):5-14. doi: 10.2478/bjmg-2021-0009. eCollection 2021 Jun.
8
FH through the retrospectoscope.
J Lipid Res. 2021;62:100036. doi: 10.1194/jlr.TR120001001. Epub 2021 Feb 6.

本文引用的文献

2
Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
Atherosclerosis. 2018 Oct;277:448-456. doi: 10.1016/j.atherosclerosis.2018.06.819.
3
Simplified Canadian Definition for Familial Hypercholesterolemia.
Can J Cardiol. 2018 Sep;34(9):1210-1214. doi: 10.1016/j.cjca.2018.05.015. Epub 2018 May 19.
4
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044.
5
A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1704-1714. doi: 10.1210/jc.2017-02622.
6
Familial hypercholesterolemia: experience from France.
Curr Opin Lipidol. 2018 Apr;29(2):65-71. doi: 10.1097/MOL.0000000000000496.
7
Familial hypercholesterolemia: experience from the French-Canadian population.
Curr Opin Lipidol. 2018 Apr;29(2):59-64. doi: 10.1097/MOL.0000000000000487.
8
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).
Atheroscler Suppl. 2017 Oct;29:11-16. doi: 10.1016/j.atherosclerosissup.2017.07.001.
10
Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries.
J Clin Lipidol. 2017 Jan-Feb;11(1):160-166. doi: 10.1016/j.jacl.2016.11.004. Epub 2016 Nov 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验